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Background: FGF21 is a promising intervention therapy for metabolic diseases as fatty liver, obesity and diabetes.
Recent results suggest that FGF21 is highly expressed in hepatocytes under metabolic stress caused by starvation,
hepatosteatosis, obesity and diabetes. Hepatic FGF21 elicits metabolic benefits by targeting adipocytes of the
peripheral adipose tissue through the transmembrane FGFR1-KLB complex. Ablation of adipose FGFR1 resulted in
increased hepatosteatosis under starvation conditions and abrogation of the anti-obesogenic action of FGF21.
These results indicate that FGF21 may be a stress responsive hepatokine that targets adipocytes and adipose tissue
for alleviating the damaging effects of stress on the liver. However, it is unclear whether hepatic induction of FGF21
is limited to only metabolic stress, or to a more general hepatic stress resulting from liver pathogenesis and injury.
Methods: In this survey-based study, we examine the nature of hepatic FGF21 activation in liver tissues and tissue
sections from several mouse liver disease models and human patients, by quantitative PCR, immunohistochemistry,
protein chemistry, and reporter and CHIP assays. The liver diseases include genetic and chemical-induced HCC, liver
injury and regeneration, cirrhosis, and other types of liver diseases.
Results: We found that mouse FGF21 is induced in response to chemical (DEN treatment) and genetic-induced
hepatocarcinogenesis (disruptions in LKB1, p53, MST1/2, SAV1 and PTEN). It is also induced in response to loss of
liver mass due to partial hepatectomy followed by regeneration. The induction of FGF21 expression is potentially
under the control of stress responsive transcription factors p53 and STAT3. Serum FGF21 levels correlate with FGF21
expression in hepatocytes. In patients with hepatitis, fatty degeneration, cirrhosis and liver tumors, FGF21 levels in
hepatocytes or phenotypically normal hepatocytes are invariably elevated compared to normal health subjects.
Conclusion: FGF21 is an inducible hepatokine and could be a biomarker for normal hepatocyte function. Activation
of its expression is a response of functional hepatocytes to a broad spectrum of pathological changes that impose
both cellular and metabolic stress on the liver. Taken together with our recent data, we suggest that hepatic FGF21
is a general stress responsive factor that targets adipose tissue for normalizing local and systemic metabolic
parameters while alleviating the overload and damaging effects imposed by the pathogenic stress on the liver. This
study therefore provides a rationale for clinical biomarker studies in humans.
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Fibroblast growth factor 21 (FGF21) is an atypical member
of the ligand family of the FGF signaling system [1]. It acts
as an endocrine factor with important roles in regulating
the homeostasis of lipid, glucose and energy metabolism
[2,3]. FGF21 directly elicits these effects through binding
to a transmembrane protein complex consisting of a con-
ventional FGF receptor (FGFR) tyrosine kinase and a co-
factor betaKlotho (KLB) in adipocytes of the adipose tissue
[4-10]. Hepatic FGF21 and adipose FGFR1-KLB constitute
a negative regulatory axis for lipid, carbohydrate and en-
ergy metabolism in maintaining overall metabolic homeo-
stasis. This is in parallel to the axis of ileal FGF19 to
hepatic FGFR4-KLB for negative regulation of bile acid
synthesis, and bone FGF23 to kidney FGFR-Klotho (KL)
for negative regulation of mineral metabolism. In animal
studies, overexpression or pharmacological administration
of FGF21 ameliorates fatty liver, obesity and type 2 dia-
betes without a hyperproliferative side-effect characteristic
of paracrine and autocrine-acting heparan sulfate-binding
FGFs [3,11-13]. These effects are likely achieved by: (1)
stimulating energy expenditure and futile cycling and
regulating lipolysis, fatty acid oxidation and glucose utili-
zation directly in white and brown adipose tissues; and (2)
indirectly reducing lipogenesis and hepatosteatosis through
enhancing triglyceride clearance, β-oxidation and ketoge-
nesis in the liver [2,3,11-14].
Similar to FGF19 (FGF15 in mouse) and FGF23, the
other two members of the FGF19 subfamily, these effects
of FGF21 are determined by the tissue-specific expression
and signaling of different isoforms of FGFRs and KLB. Re-
cent studies indicate a specificity of FGF21 for FGFR1-
KLB in adipose tissues [5,8,9,15]. On the other hand, the
liver appears to be the primary source of circulating
FGF21. In the normal fed state, the expression of FGF21 is
only detectable at a low level in the liver. However, in re-
sponse to fasting and starvation, a ketogenic diet, NAFLD,
steatosis, obesity and type 2 diabetes, the expression of
FGF21 is increased significantly [2,16-22]. Treatments with
rosiglitazone, pioglitazone, metformin and other PPAR ag-
onists induce hepatic FGF21 expression [19,23]. High-fat
diets, which cause NAFLD and NASH, induce FGF21 in
the liver [24-26]. Liver transplantation or HIV infection in
liver increases serum FGF21 level [27,28]. Ablations of se-
veral functionally distinct proteins in hepatocytes, such as
Foxo1, BDNF, gp78, Nrf2 and TBP-2 that result in me-
tabolic and cellular abnormalities, coincide with increase
of FGF21 expression [29-33]. At the intracellular level, ER
stress, mitochondrial respiratory chain deficiency and an
autophagy deficit also induce FGF21 expression [34-37].
Although some other studies suggest that FGF21 may be
also expressed by extra-hepatic tissues under PPARγ or
ATF2 control, such as white adipose tissue (WAT), brown
adipose tissue (BAT), pancreas and skeletal muscle[38-40], the extrahepatic expression appears to be rela-
tively low and occurs under specific stress conditions, and
does not contribute to serum FGF21 levels as significantly
and broadly as the liver.
The induction of hepatic FGF21 expression by diverse
types of hepatic stress indicates that FGF21 is a stress-
responsive hepatokine that is activated during liver patho-
genesis and injury that impinge on its normal metabolic
functions in behalf of the organism. Induced FGF21 in
turn acts as a secretory signal that targets predominantly
the adipose tissue adipocytes for assistances (compensa-
tion or reduction) in normalizing metabolic parameters in
order to maintain lipid and energy metabolic homeostasis.
This in turn serves to reduce the potentially damaging ef-
fects on the liver imparted by the stress. This idea is in
concert with recent results indicating that, FGF21 of pre-
dominantly hepatic origin acts specifically on FGFR1-KLB
in adipose tissue, as a primary endocrine axis for regulat-
ing both hepatic and systemic lipid, glucose and energy
metabolism [5,6,8-10]. However, the breadth of the stress
that remarkably activates hepatic expression of FGF21 is
unclear. Induction of hepatic FGF21 expression may be a
general property of functional hepatocytes in response to
liver stress caused by not only metabolic extremes, but
also tumorigenesis, liver damage and chronic diseases. To
test the hypothesis that FGF21 is a hepatokine induced by
general hepatic stress signals, here we investigate the in-
duction of FGF21 in the liver under several major types of
liver perturbation including liver injury and regeneration,
chemical and genetic hepatocellular carcinogenesis (HCC)
in both mouse models and human patient samples. Taken
together with other studies, we conclude that FGF21 is an
indicator of liver function and stress, and has the potential
to be a predictive biomarker for liver function test, early
diagnosis of liver cancer, other hepatic diseases and
minimally-invasive clinical analysis. Increased serum
FGF21 that originates from the liver under stressful condi-
tions may serve in an inter-organ feedback communica-
tion network involving the liver and adipose tissue, which
results in minimizing the damaging effects on the liver
caused by the stress. In addition to several nuclear recep-
tors, we implicate other stress response factors such as
p53 and STAT3 in the regulation of hepatic FGF21 ex-
pression that warrant further investigation.
Methods
Mouse hepatocellular carcinoma models
Mice were handled in accordance with the principles and
procedure in the Guide for the Care and Use of Labora-
tory Animals. All experimental procedures were approved
by the Institutional Animal Care and User Committee
(IACUC).
Diethynitrosamine (DEN)-induced HCC was done as
previously described [41]. In brief, cohorts of male C57BL/
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traperitoneally (IP) at 10 mg/Kg body weight. Control mice
were injected IP with PBS. Liver tissues from the left lobe
were collected at 0, 0.25, 2, 4, 6, 8, 10, 12 and 14 month
after injection, minced and frozen at −80°C, or fixed over-
night in 4% PFA in 1 × PBS. Paraffin-embedded tissue
blocks were sectioned into 5 μm slides for H&E staining
or immunohistochemical (IHC) analyses.
The LKB1+/− and LKB1+/−p53+/− mouse lines were
prepared as described [42]. Liver tissues from wildtype
and mutant mice at one year of age were collected for
mRNA extraction and gene expression analyses.
Mouse strains with liver-specific ablation of the Hippo
pathway component SAV1 (SAVf/fAlbCre) or MST1 and
MST2 (MST1/2f/fAlbCre) by Albumin (ALB) promoter
driven Cre were prepared as described [43]. Mouse liver
tissues and sera from wildtype and liver-specific knock-
out mice at 6, 12 or 24 month were collected for gene
expression and serum protein analyses.
Mice with liver-specific ablation of PTEN were generated
by cross-breeding PTENlox/lox mice with ALB-Cre mice
and liver tissues from PTENlox/lox and PTENlox/loxAlbCre
mice were collected at one year of age.
Mouse lines deficient in FGFR4 (FGFR4−/−) or KLB
(KLB−/−) were prepared as described [8], and liver tissues
were collected for gene expression analyses at one year
of age.
Partial Hepatectomy (PHx)
For 70% hepatectomy, C56BL/6J mice were anesthetized
by inhalation of isoflurane. The left lateral and medium
lobes were ligated and removed. Liver tissues (right
lobes) and sera were collected at 0.5, 1, 2, 3, 4, 7 days
post-surgery for mRNA expression and protein analyses.
Gene expression analyses
Total RNA isolation, first-strand DNA synthesis, primer de-
sign and quantitative PCR analysis were performed as de-
scribed [8]. Primer pairs for analyzing the expressions of
FGF21, FGFR4, KLB and ALB genes are 50-TTCAAATCC
TGGGTGTCAAA and 50-CAGCAGCAGTTCTCTGAA
GC, 50-CAGAGGCCTTTGGTATGGAT and 50-AGGTCT
GCCAAATCCTTGTC, 50-CAGAGAAGGAGGAGGTGA
GG and 50-CAGCACCTGCCTTAAGTTGA, and 50-ACC
CCGAAGCTTGATGGTGTGAAG and 50-GCAAGTCT
GCAGTTTGCTGGAGAT respectively.
Analyses of serum FGF21 protein levels
Serum was obtained from mice at the times as indicated
in the text. Soluble KLB (sKLB) with transmembrane
and intracellular domains replaced by 6 × His tag was
produced in T-Rex 293 cells by tetracycline induction as
described [44]. sKLB secreted into the culture medium
was immobilized on Ni-Chelating beads. Aliquots ofsKLB-bound beads were used to enrich FGF21 from
mouse sera, which was then analyzed by western blot-
ting with anti-FGF21 antibody (Cat #ab66564, Abcam
Inc, MA) and quantified by densitometry.
Where indicated, plasma FGF21 concentration was also
determined in duplicate by a mouse-specific ELISA kit
(EMD Millipore, Billerica, MA) according to the manufac-
turer’s protocol in an effective range of 50–12000 pg/ml.
The coefficient of variation was less than 10% within
a same analysis and less than 8% between separate
analyses.Immunohistochemical (IHC) analysis of FGF21 in mouse
liver tissue section
Twelve mouse liver sections (5 μm) for each experimental
condition were treated at 100°C to retrieve antigens in
a pressure steamer containing 10 mM citrate buffer
(pH 6.0) for 1 hr. The sections were de-paraffinized, hy-
drated and then immersed in 0.3% hydrogen peroxide for
20 min and incubated in 5 μg/ml anti-FGF21 antibody
(Cat #ab66564, Abcam Inc, MA; http://www.abcam.com/
FGF21-antibody-ab66564.html) containing 1 mg/ml BSA
overnight. Second anti-rabbit IgG-Biotin and ExtrAvidin
conjugated to peroxidase (Sigma-Aldrich, St. Louis, MO)
were used for enzymatic colorigenic staining with AEC
(N,N-dimethylformamide) as the chromogen. The section
was then counterstained with haematoxylin and mounted
with DPX. The slides were analyzed by a pathologist and
photographed digitally by light microscopy.
IHC analyses of FGF21 in tissue microarrays of normal
and diseased human livers
Human liver tissue microarrays were obtained from US
Biomax Inc, with an ethic statement, “All tissue is col-
lected under the highest ethical standards with the
donor being informed completely and with their con-
sent. We make sure we follow standard medical care
and protect the donors’ privacy. All human tissues are
collected under HIPPA approved protocols. All samples
have been tested negative for HIV and Hepatitis B or
their counterparts in animals, and approved for com-
mercial product development”.
The use of these commercially available and processed
human tissue microarrays for research work followed In-
stitutional Review Board (IRB) standards. IHC staining
described above for expression of FGF21 in human livers
was performed on 5 μm unstained microarray slides
(#LV1201 and LV803). The LV1201 array contains 25
HCC, 14 normal liver tissues, 16 fatty degeneration, 21
chronic active hepatitis, 30 cirrhosis, 3 cysts and 10
hemangioma cases. The LV803 microarray contains 26
sets of HCC with matched or unmatched tumor tissues
and tumor adjacent phenotypically normal tissues.
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Luciferase reporter constructs with human FGF21 pro-
moter sequence, FGF21 +5, -98, -997 and −1497 in TK-
Luc were provided by Dr. Steven Kliewer (The University
of Texas Southwest Medical Center) [2]. pFGF21 +11, -
289, -443 and −1.6 K in PGL4.12 were from Dr. Yutaka
Taketani (University of Tokushima, Japan) [45]. Wildtype
and mutant constructs of p53 were from Dr. Weiqin Lu
(University of Texas MD Anderson Cancer Center, Uni-
versity of Texas). Hep3B cells cultured in 12-well plate in
DMEM high-glucose medium supplemented with 7% FBS,
were transfected with these constructs with 15 μg/ml poly
(ethylenimine) for 2 hrs. Empty vectors were used as con-
trols. After further culture for 48 hr, the luciferase assay
was performed according to manufacturer’s protocol using
beetle Luciferin as the substrate in the presence of ATP
and CoA (#E1500, Promega, Madison, WI).
CHIP Assay
Chromatin immunoprecipitation (CHIP) analyses for p53
and STAT3 binding in the FGF21 promoter regions were
done in Hep3B cells according to the manufacturer’s assay
protocol (#17-371 EZ-CHIP, EMD Millipore). Lysates
containing chromosomal DNA from about 1x106 95% con-
fluent Hep3B cells were sheared to an average size of 1 to
5 kb fragments by ultrasonication and immunoprecipitated
(IP) by anti-p53 (FL-393) (#SC-6243, Santa Cruz Biotech-
nology) and anti-pTyr705-STAT3 (#9131, Cell Signaling
Technologies). Quantitative PCR using the SYBR Green
JumpStart Taq Ready Mix (Sigma) on the Stratagene
Mx3000P qPCR system was then applied to determine the
binding sites of p53 and STAT3. Primers were designed to
amplify about 200 bp encompassing the putative sites pre-
dicted by an in silico program based on the human FGF21
chromosome DNA sequence (http://www.sabiosciences.
com/chipqpcrsearch.php). Normal mouse or rabbit IgG
and anti-RNA polymerase II antibody were negative and
positive controls, respectively. Lysates with sheared DNA
without IP were used as sample input. Primer pairs 50-
AGACCCAGGAGTCTGGCC and 50-GGGATAGATGCA
GAAGCT, and 50-CTCCAGAAGATGCCAGGC and 50-
CTCCAGAAGATGCCAGGC were used for analyses of
p53 binding sites A (−191 to −215) and B (−6016 to −
6026), respectively, by quantitative PCR. Primer pairs 50-
AGAGTTCCAGAGGAGGAT and 50-AAGTGAGGCCCA
GTGGGA, 5v-GCAGATAGTCCCGACGGC and 50-GGA
ACAGATCCGCAGAGA, and 50-GAGCCACGAAGTGG
ACAT and 50-CCTCCGCGTGGGCAGAAG were used to
identify STAT3 binding sites A (+2269 to +2276), B and C,
respectively.
Statistical analysis
Experiments were reproduced three times independently
with triplicates in each experiment. Photomicrographsare representative of three or more experiments. Where
indicated, the mean and standard deviation (sd) were
reported. Comparisons between different genotype groups
were performed with the unpaired t test. Values were
deemed to be statistically significantly different at p ≤ 0.05.
Results
FGF21 is induced following mouse liver injury
The expression of FGF21 is relatively low in the liver,
and undetectable in muscle, WAT, BAT (Figure 1A),
ileum and pancreas (not shown) in the fed state on a
normal diet. After starvation for 48 hrs that induces
hepatic steatosis, the expression of FGF21 was induced
more than 220 fold exclusively in the liver (Figure 1A),
which was about 22 times that in the fed state. Extrahe-
patic tissues did not exhibit such a remarkably inducible
response to starvation.
To further test the idea that hepatic FGF21 expression
indicates the functional status and perturbation of the
liver, we first examined hepatic FGF21 mRNA after a
partial hepatectomy that transiently reduces the full
functional capacity of the liver until regeneration is
complete. The expression of FGF21 was increased more
than 30 times in the first 12 hrs to 2 day of regeneration
after 1/3 PHx (Figure 1B), and gradually decreased in
the course of liver regeneration and returned to normal
basal levels after one week. The corresponding serum
FGF21 was first enriched by binding to 6 × His tagged
soluble KLB protein immobilized on Ni2+-Chelating
beads [44], and then detected by antibody in western
blot analysis. The levels of serum FGF21 protein
(Figure 1B inset) followed the same pattern as hepatic
mRNA levels determined by quantitative PCR analysis.
In contrast, the expression of hepatic KLB followed an
opposite pattern to that of FGF21 (Figure 1C). The ex-
pression of hepatic resident FGFR4 remained relatively
unchanged (Figure 1D). The peak changes in the expres-
sions of FGFR4 and KLB were about 1.4 and 0.09 times
that of the livers before PHx, respectively. This indicates
that FGF21 is an acute hepatic secretory factor in re-
sponse to reversible loss of liver mass and functional
capacity.
FGF21 is induced in mouse hepatocytes during genetic
hepatocarcinogenesis
To determine whether FGF21 expression is induced in he-
patocytes during hepatic tumorigenesis, we analyzed the
expression of FGF21 in several HCC models. The tumor
suppressor LKB1 heterozygous knockout mice developed
spontaneous HCC upon aging [42,46]. The expression
of FGF21 was increased about 6 fold in the LKB+/−
haploinsufficient livers (Figure 2A), and strikingly more
than 30 fold in the compound p53+/−LKB1+/− mouse livers
compared to the wildtype counterparts. In contrast, the
Figure 2 Elevation of hepatic FGF21 expression during genetic hepatocarcinogenesis and perturbation. Hepatic FGF21 mRNA levels were
analyzed by quantitative PCR in the mouse liver tissues under different perturbation conditions at an age of one year. mRNA levels are expressed
as fold changes relative to that in the wildtype or control mouse livers, which is assigned as an arbitrary unit 1. A: Increase of FGF21 mRNA levels
in mouse livers with haploinsufficiency for tumor suppressors LKB1 and p53. Changes in expression of FGFR4 and KLB were also measured in the
corresponding tissues. *p < 0.05 (n = 6). WT: wildtype. B: Increase of FGF21 mRNA levels in mouse livers with conditional ablation of tumor
suppressors SAV1, compound MST1/MST2 or PTEN. f/f: floxed alleles for SAV1, MST1/MST2 or PTEN genes. −/−: ALB-Cre mediated hepatic deletion
of SAV1, MST1/MST2 or PTEN. *p < 0.05 (n = 3-5 for each data point). C: Changes in the corresponding serum FGF21 protein levels in mice used in
(B) were determined as in Figure 1B inset. D: Changes of hepatic FGF21 mRNA levels after whole-body knockout of KLB or FGFR4. *p < 0.05 (n = 6
for each data point). KO: whole-body knockout.
Figure 1 Liver is the source of FGF21 elevation upon dietary restriction and liver damage. The FGF21 expression level was analyzed by
quantitative PCR in the indicated mouse tissues under different conditions. A: Increase of FGF21 mRNA levels specifically in mouse livers after
prolonged starvation for 48 hrs. mRNA levels are expressed as fold changes relative to the internal β-actin levels in the respective tissues. WAT:
white adipose tissue. BAT: brown adipose tissue. Data are shown as mean ± sd, *p (n = 6) <0.05. B: Induction of hepatic FGF21 mRNA in the liver
after PHx. mRNA levels at different time lapses after PHx are expressed as fold changes relative to that before PHx. *p <0.05 (n = 3 for each data
point). Inset: the corresponding serum FGF21 protein levels were determined by soluble KLB (sKLB) pulldown and western blotting analyses as
described in the Method section. C: Changes of hepatic KLB mRNA levels after PHx. D: Changes of hepatic FGFR4 mRNA levels after PHx. Total
RNA samples for analyses of KLB and FGFR4 expression are the same as for FGF21 in (B).
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tional hepatic ablation of Hippo pathway component
SAV1 or compound MST1/2 also resulted in hepatic
tumor formation. This was accompanied by an increase of
16 and 22 times in FGF21 expression in the livers
of SAVf/fAlbCre and MST1/2f/fAlbCre mice, respectively
(Figure 2B). The serum protein levels of FGF21 also
followed the mRNA pattern (Figure 2C). Hepatic ablation
of PTEN as a tumor suppressor and the PI3K/AKT signal
controller, which resulted in fatty liver and hepatocellular
carcinoma [47], also upregulated FGF21 expression at
about 25 times in the PTENf/fAlbCre livers than those of
PTENf/f controls (Figure 2B).
Consistent with genetic alterations in genes that result
in liver cancer, genetic deficiency that causes metabolic
perturbations without tumorigenesis in the livers also in-
duced hepatic FGF21 expression. Both FGFR4 and KLB
are highly expressed in the liver and mediate the effects
of FGF19 but not FGF21 [8,44,48]. Deficiency of either
FGFR4 or KLB significantly disrupted the ability of liver
to regulate bile acid homeostasis. We found that theFigure 3 Potential regulation of hepatic FGF21 expression by p53 and
promoter sequences. Potential p53 binding locus and sequence conservati
human, mouse and rat species. Reporter assays were performed in Hep3B
plasmids (−1497, -443 and −97) or control plasmid (+5) in the absence (gra
and mutant (open bar). Cells were maintained in high glucose medium. Da
B: Determination of p53 and STAT3 binding regions. CHIP assay was perfor
enrichment of DNA regions were analyzed by qPCR and expressed as perc
control for p53 and active STAT3 antibodies. Values are means ± sd of duplicaexpression of FGF21 was increased by 5 and 10 times in
FGFR4−/− and KLB−/− livers, respectively, over the
wildtype controls under these conditions (Figure 2D).
Our data suggest that haploinsufficiency of p53 signifi-
cantly affects FGF21 expression (Figure 2C). As p53 is a
transcription factor and plays important roles in liver
cancer, liver diseases and metabolic regulation, and loss
of p53 function is known to contribute to tumorigenesis,
it may regulate the expression of FGF21 gene under cer-
tain hepatic stress conditions, such as tumorigenesis. In
silico analysis revealed an atypical p53 transcription fac-
tor binding site A, GGTGATTGGGCGGGCCTGTCT,
at −191 to −215 bp upstream of the ATG translational
start site of FGF21 gene (http://www.mybioinfo.info)
(Figure 3A). This sequence in the proximal promoter re-
gion of FGF21 is conserved across human, mouse and
rat species (Figure 3A). Luciferase reporter assay with
the FGF21 promoter and upstream regions showed that
p53 negatively regulate FGF21 expression in Hep3B cells
cultured in high glucose medium (Figure 3A). This
wildtype p53 effect was significantly abrogated by a mu-STAT3. A: Luciferase reporter activities with different FGF21
on in the proximal region of FGF21 promoter were shown across
cells co-transfected with the indicated FGF21-luciferase reporter
y bar) or presence of expression plasmids for p53 wildtype (black bars)
ta are shown as mean ± sd, * p < 0.05 (n = 3 for each data point).
med as described in the Methods section in Hep3B cells. Antibody
ent recovery relative to the inputs. Normal IgG was used as negative
te PCRs performed at least three times with similar results, * p < 0.05.
Figure 4 Elevation in FGF21 expression during DEN-induced
hepatocarcinogenesis. A: Temporal changes of hepatic FGF21
mRNA levels in mouse livers following initial treatment with DEN.
FGF21 and ALB mRNA levels were analyzed by quantitative PCR in the
mouse liver tissues during different time courses of DEN-induced
tumorigenic effect. mRNA levels are expressed as fold changes relative
to that injected with PBS, which is assigned as an arbitrary unit 1.
*p < 0.05 (n = 3-4 for each time point). B: Immunohistochemical
analyses of FGF21 protein levels in mouse liver sections (cytosolic
maroon stains) before DEN injection or 2, 4, 6, 8 and 12 month after
DEN injection. There is only scattered staining in the sections from the
livers at 12 months post-injection (green arrowheads). Data are
representatives for FGF21 antigens from the livers of 3–5 mice at each
time point. Green arrowhead: concentrated cytoplasmic FGF21
staining; Yellow arrow: enlarged or irregular nuclei; Black asterisk: lipid
droplet; Blue arrow: fibrotic cirrhotic area.
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scription activation domain and part of the DNA-
binding domain (1-Met246 deletion) but still contains
the C-terminal oligomerization domain (Figure 3A).
These data support the idea that FGF21 is an independ-
ent indicator of genetic hepatocarcinogenesis. p53 may
account for an additional or combinatory mechanism for
regulating FGF21 expression in association with liver
damage and carcinogenesis beyond metabolic alterations
regulated by several nuclear receptors (NRs).
CHIP and quantitative PCR analyses revealed another
potential p53 binding region surrounding putative site B
of GAGACAAGTCT at −6016 to −6026 bp from the ATG
site (Figure 3B) (http://www.sabiosciences.com/chipqpc
rsearch.php). Among several predicted putative sites (see
Methods section), the region surrounding site A of GGCT
TCCC sequence at +2269 to +2276 bp was also found to
bind STAT3 in these assays (Figure 3B). These results in-
dicate that induction of FGF21 expression is potentially
controlled by multiple transcription factors that presum-
ably respond to different stress conditions.
FGF21 is induced in mouse hepatocytes during chemical
damage and hepatocarcinogenesis
Upon a single injection of hepatic carcinogen DEN at an
age of two weeks to induce HCC, the expression of FGF21
increased significantly in the early stage when chemical
damage is apparent before overt carcinogenesis is evident.
The increases were apparent in the first week after treat-
ment and have a peak induction of over 27 times at 2 to
4 months compared to mouse livers injected with PBS
(Figure 4A). IHC analyses of FGF21 in mouse liver sec-
tions with anti-FGF21 antibody (#ab66564, Abcam Inc)
following DEN treatment revealed a remarkable increase
of FGF21 protein in the cytoplasm of phenotypically nor-
mal hepatocytes (green arrowheads) in the early and mid-
dle stages of hepatic carcinogenesis at 6–8 months, as
compared to the same without DEN injection (0 month)
(Figure 4B). The cytosolic maroon color staining was uni-
formly high in the sections from 2, 4, 6 and 8 months.
There was no or only weak staining in the section before
DEN injection (0 month), and only scattered weak stains
in the sections of the livers treated with DEN for
12 months, where hyperplasia and tumor foci occurred.
FGF21 expression was lost or attenuated in cells with ab-
normal and irregular expansion of nuclei (yellow arrows)
accompanied by focal steatosis (black asterisks) and cir-
rhosis (blue arrows) in surrounding hepatocytes (Figure 4B.
6, 8 and 12 months). In contrast, the expression of hepatic
albumin during the first six month period remained essen-
tially unaltered, and exhibited only a 35% reduction at
14 months post DEN injection as compared to PBS con-
trol (Figure 4A). This indicates that FGF21 expression is
lost as cells progress to malignancy, while the remainingscattered phenotypically normal hepatocytes adjacent to
the hyperplasia or tumor foci still express FGF21 at highly
elevated levels (Figure 4B. 12 month).
We further analyzed the serum levels of FGF21 as a
hepatic hormone by ELISA upon hepatocarcinogenesis.
A similar trend of increase was observed in the serum
samples taken from the corresponding mice used for
mRNA analyses (Figure 2B, 4A), albeit with much less
extent of increase (Figure 5). Hepatic ablation of SAV1
and compound MST1/2 increased the serum FGF21
levels from 0.29±0.017 and 0.37±0.026 ng/ml in the con-
trol mice to 0.87±0.056 and 1.24±0.068 ng/ml in the
mutant mice, respectively (Figure 5A). DEN treatment
led to an increase of serum FGF21 protein levels similar
to that of hepatic mRNA induction (Figure 5B, 4A). The
Figure 5 Increases of serum FGF21 protein levels in mice
undergoing hepatocarcinogenesis. Protein levels in sera obtained
from mice as indicated were determined by ELISA as described in
the Methods section. 20 μl plasma from each mouse was analyzed
in duplicate. A: Changes of serum FGF21 levels in mice with
deficiency in Hippo pathway components SAV1 and compound
MST1/2 (Figure 2B). B: Temporal changes of serum FGF21 levels in
mice following DEN-induced hepatocarcinogenesis (Figure 4A).
*p < 0.05 (n = 3-4 for each time point).
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4 months of age following DEN treatment, compared to
0.31 ng/ml in the untreated mice.
Our data indicate that FGF21 is a hepatokine induced
in phenotypically normal hepatocytes upon acute car-
cinogen treatment and chronic carcinogenic transform-
ation, and liver damage and partial resection resulting in
reduced liver function. Changes in its hepatic expression
or serum protein levels potentially mark the function of
hepatocytes, but not malignant hepatocellular carcinoma
cells that have lost their hepatocyte identity. These data
concerning FGF21 expression are consistent with the
notion that FGF21 is a property of differentiated hepato-
cytes and induced by agents perturbing normal liver that
leads to liver tumorigenesis and disease pathogenesis.
However, its expression is not a direct genetic marker of
hepatoma cells per se.
FGF21 expression is increased in regions surrounding the
human hepatic lesions
To evaluate the clinical significance of FGF21 expression in
association with human HCC and liver diseases, we
analyzed FGF21 expression by IHC analyses with anti-
FGF21 antibody in clinically dissected, proven and graded
liver tissue sections from human patients with known di-
verse causes of liver diseases. Among 46 human HCC and
5 cholangiocellular carcinoma sample sections examined,
all grade 1 HCC areas of well-differentiated cells (Figure 6A)
and all hepatocytes in tumor-adjacent (≥ 1.5 cm from the
edge of the tumor foci) (Figure 6B, D, F) and phenotypically
normal liver areas (as represented in Figure 6H from pa-
tients having different grades of HCC) from grade 1–3
HCC patients, exhibited a high level of staining for FGF21
(as represented by the green arrowheads). This was in
marked contrast to the gradually diminished or lost expres-
sion of FGF21 in the HCC foci areas with grade 2 ofmoderately-differentiated (Figure 6C) and grade 3 of poorly
differentiated tumor cells (Figure 6E). Normal hepatocytes
(Figure 6G) in 10 out of 14 liver sections from healthy pa-
tients showed no or weak staining, and only 4 sections
showed a moderately high level of staining with unknown
causes. This was also evident in cholangiocellular carcin-
oma with bile duct epithelium proliferation (yellow arrows)
(Figure 7A) and clear cell-type hepatocellular carcinoma
(Figure 7C) with no or weak FGF21 expression in tumor
cells; however, FGF21 was highly expressed in fields adja-
cent to tumors (Figure 7B, D) and in phenotypically normal
hepatocytes (as represented in Figure 6H). Cirrhosis was
often observed in otherwise phenotypically normal areas
adjacent to tumors (Figure 6B, D, F; Figure 7B, D).
Hepatocytes in livers showing fatty degeneration
(black asterisks) from all 16 patients (Figure 7E), and he-
patocytes or regenerative hepatic tissues (shown inside
the black broken line) containing nodular cirrhosis or
fibrotic lesions (blue arrows and outside the black
broken line) from all 30 patients (Figure 7F), exhibited
an intense FGF21 signal. The cells within cirrhotic and
fibrotic foci showed no expression of FGF21. Nineteen
of 21 liver sections with chronic or active viral hepatitis
inflammation showed a comparably high level of FGF21
signal to that of Figure 7G, and the rest showed a weaker
but still stronger signal than livers from normal healthy
individuals. FGF21 expression was also high in hepatic
tissues (right of the black broken line) adjacent to the
wall of liver cysts, but not the cells in cyst lesions (left of
the black broken line) (Figure 7H). Taken together, these
data show that the mouse models recapitulated the fin-
dings in human liver diseases, and FGF21 expression is
significantly induced in hepatocytes in response to per-
turbation of liver functional capacity by liver damage
(viral infection, cirrhosis, steatosis and toxins), partial
resection and carcinogenic transformation (HCC, clear
cell HCC and cholangiocellular carcinoma).
Discussion
In this survey, we analyzed the nature of the stress that ac-
tivates the expression of hepatic FGF21. We found that
the expression of FGF21 was significantly induced in the
liver following reversible perturbation such as partial hep-
atectomy and regeneration, hepatosteatosis as well as irre-
versible hepatic damage from chronic hepatitis, cirrhosis,
and chemical and genetic hepatocarcinogenesis in mouse
models and human patient samples. Our data suggest that
FGF21 is an inducible stress-sensing hepatokine, and its
expression is associated with the loss of normal functional
capacity of hepatocytes due to pathogenic processes. Our
data are also supported collectively by other spontaneous
reports indicating that FGF21 is preferentially induced in
the liver upon fasting and starvation, steatosis, obesity,
type 2 diabetes and genetic deficiency of specific genes in
Figure 6 Upregulation of FGF21 expression in human hepatic tissues during HCC development. The expression levels of FGF21 were
assessed by IHC (cytosolic maroon or orange stains) with anti-FGF21 antibody in the liver tissue sections from human patients as described in the
Methods section. Representative images taken by light microscopy were shown for the following disease conditions: (A) grade 1 HCC tissues and
(B) the tumor-adjacent (≥1.5 cm from the edge of tumor foci) hepatic tissues, (C) grade 2 HCC tissues and (D) the tumor-adjacent hepatic tissues,
(E) grade 3 HCC tissues and (F) the tumor-adjacent hepatic tissues. This is in contrast to the normal hepatic tissues from healthy individuals
(G), and phenotypically normal liver tissues (H) from the HCC patients. Low-magnification (×100) images are on the left, and black-boxed sections
are enlarged (×1000) on the right. Green arrowhead: concentrated cytoplasmic FGF21 staining; Yellow arrow: enlarged or irregular nucleus; Blue
arrow: fibrotic cirrhotic area.
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clude that FGF21 is a novel hepatokine and marker for
the functional status of mature/differentiated or pheno-
typically normal hepatocytes during the process of liver
injury, recovery and pathogenesis. Since serum FGF21
originates predominantly from the liver in all these condi-
tions, it is potentially a minimally-invasive biomarker for
diagnosis and follow-up of clinical conditions including
hepatocarcinogenesis, fatty degeneration, chronic and he-
patitis inflammation, and liver damage and regeneration
in general. Under carefully controlled test conditions, he-
patic or serum levels of FGF21 could be an independent
biomarker of liver pathological changes, or a combinatory
biomarker with other existing biomarkers, such as the as-
partate aminotransferase/alanine aminotransferase ratio
(AST/ALT). Our results provide strong rationale for ex-
tensive clinical validation of the association and standar-
dization of test conditions.Several reports have shown that hepatic expression of
FGF21 is regulated by nuclear receptor PPARα/RXRα
upon fasting and starvation that change the levels of
fatty acids, the natural ligand of PPARα, or by treatment
with PPARα agonists [2,16,50]. This is similar to other
NRs that regulate the expression of the other two mem-
bers of the endocrine FGF subfamily under diverse con-
ditions [51]. FGF19 induced by postprandial bile acids
and ligands of the farnesoid X receptor (FXR) in the
ileum regulates distal hepatic cholesterol/bile acid syn-
thesis [51] and systemic lipid metabolism [52]. Vitamin
D and the vitamin D receptor regulate FGF23 expression
in bone, which in turn negatively impacts mineral me-
tabolism in the kidney [53]. Other studies indicate that
hepatic FGF21 expression is also regulated, either posi-
tively or negatively, by ChREBP, PPARγ, LXR or FXR/
RXRα in diverse conditions [17,45,54,55]. In this study,
we show that beyond NRs, the stress regulators p53 and
Figure 7 Upregulation of FGF21 expression in human hepatic tissues undergoing other diverse pathologies. The expression levels of
FGF21 (cytosolic maroon or orange stains) were assessed by IHC as in Figures 4 and 6 in the liver tissues having the following disease conditions:
cholangiocellular carcinoma (A) and the adjacent hepatic tissues (≥1.5 cm from the edge of tumor foci) (B), clear cell hepatocellular carcinoma
(C) and the adjacent hepatic tissues (D), fatty degeneration (E), cirrhosis and the adjacent hepatic tissues (F), viral hepatitis (G), and liver cyst and
the adjacent hepatic tissue (H). Low-magnification (×100) images are on the left, and black-boxed sections are enlarged (×1000) on the right.
Green arrowhead: concentrated cytoplasmic FGF21 staining; Yellow arrow: enlarged or irregular nucleus; Blue arrow: fibrotic cirrhotic area; Black
asterisk: lipid droplet; Black broken line: the boundary between large cirrhotic lesion and the surrounded hepatic tissue island (F), or between the
fibrotic cyst and the hepatic tissue (H).
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http://www.biomedcentral.com/1471-230X/13/67STAT3 may also participate in the regulation of FGF21
expression. Deletions, mutations or change in the ex-
pression of p53 or STAT3 in hepatocytes contribute to
hepatocellular carcinoma (HCC) or liver damage [56,57].
This is consistent with our finding that FGF21 expres-
sion is regulated by wildtype p53 and STAT3. Therefore,
our results may indicate the existence of multiple mech-
anisms for regulating the expression of FGF21 in associ-
ation with the differentiated function of hepatocytes,
and damage or loss of liver function under diverse stress
conditions. This new roles of p53 and STAT3 are in har-
mony with the many roles of p53 and STAT3 in cellular
stress responses that impact cell growth, survival, death
and metabolic homeostasis. As metabolic alteration and
cell growth control are intertwined, p53 or STAT3 con-
trol of FGF21 expression could be cooperatively engaged
with PPARs or other NRs that are master response and
regulatory factors for metabolic abnormalities.As liver is the central organ for maintenance of meta-
bolic homeostasis, we expected that these stress condi-
tions, which alter metabolic functions of the liver either
directly through glucose/fat accumulation or indirectly
through cellular abnormality including tumorigenesis,
injury and damage, ultimately alter hepatic metabolites.
These metabolites, such as FFA, cholesterol or even TG,
are the output of normal liver function, and are proven
pivotal activators or inhibitors of NRs that in turn re-
gulate FGF21 expression. This is likely one of the major
or direct mechanisms through which hepatic FGF21
expression is regulated. This idea is supported by obser-
vations that the development of many metabolic and cel-
lular liver diseases from diverse causes undergoes a stage
of lipid accumulation or steatosis. NRs in conjunction
with other regulators some of which we reveal in the
current study may be the unifying mechanism by which
hepatic FGF21 expression in PHx, DEN treatment,
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is regulated. It is well-established that both p53 and
STAT3 can collaborate with NRs under many of these
stressful conditions.
Our analyses of liver tissue sections from human pa-
tients with diverse liver diseases further confirmed the no-
tion that FGF21 is a potential biomarker of human liver
diseases. Although it may not directly contribute to the
disease etiology, its expression level reflects the function
of phenotypically normal and mature hepatocytes and the
functional status of the liver as a whole. The effect of its
elevation is to counteract the overload and potentially
damaging effect in both liver and the entire organism im-
posed by the stress. Our previous studies suggest that this
is through a mechanism by which hepatic FGF21 targets
extra-hepatic adipocytes and adipose tissues via an endo-
crine mechanism for compensatory metabolic regulation
and alleviation of metabolic diseases including fatty liver,
obesity and diabetes [5,6,8-10]. An increase in hepatic
FGF21 mRNA expression correlates closely with the
serum protein level (Figures 1, 2, and 5). This indicates
that serum FGF21 may be an excellent minimally-invasive
biomarker that is sensitive, specific and of predicative
value for test of liver function and diagnosis of the onset,
stage and prognosis of various liver diseases. The next step
should be the study in a clinical setting.
Until recently, diverse extra-hepatic tissues were sug-
gested as direct targets of FGF21 via an FGFR. Although
most reports focused on effects of systemic FGF21 on
glucose uptake [3] and lipolysis in fat tissue and isolated
adipocytes [14,58,59], some suggested that FGF21 may
directly regulate, through FGF21 signaling in hepato-
cytes, the responses of the liver to fasting and ketogenic
diet, hepatic insulin sensitivity, triglyceride clearance and
hepatosteatosis [2,11,16,60]. Others argued that effects
of systemic FGF21 on liver were indirect [6,14,61,62].
This notion has been recently confirmed by direct gen-
etic manipulation of FGFR isotypes in adipocytes and
hepatocytes. Ablation of KLB or an adipose tissue-
specific deficiency of FGFR1 and FGFR2 indicates that
adipose tissue and more specifically adipocyte FGFR1,Figure 8 Plausible action and role of hepatic FGF21 induced by multi
by injury and pathologies in the liver induce elevated expression of FGF21.
peripheral adipose tissues. This results in metabolic benefits including corre
resulted from perturbation of normal liver functions. As a result of this feed
are attenuated or prevented.but not the liver, is the direct and predominant target of
serum FGF21 action [8]. Our studies in these mouse
models with DIO and administration of FGF21 further
precipitated a consensus that the entirety of metabolic
actions and pharmacotherapy effects of FGF21 is pre-
dominantly, if not solely, governed by the adipose tissue
(both brown and white adipose tissues) FGFR1-KLB
[10]. In all cases, elevation of FGF21 or treatment by
FGF21 ameliorated hepatic steatosis and other abnormal
hepatic metabolic parameters. Therefore, secreted hepa-
tokine FGF21 appears to serve a beneficial function to
the organism systemically and to the liver locally when
the liver is under stress and cannot fully perform its nor-
mal function in metabolic homeostasis (Figure 8). This
is through the axis from hepatic FGF21 to adipose
FGFR1-KLB, and likely a secondary axis from adipose to
the liver through metabolites and adipokines (such as
adiponectin) [4,8-10] (Figure 8). Such an endocrine
regulatory axis initiated by stress-responsive FGF21 re-
sults in concurrent attenuation of adipose lipolysis, hep-
atic lipogenesis and hepatosteatosis, and ultimately of
stress-imposed liver damage [9,10].
Interestingly, at the intracellular level, FGF21 can be
also significantly upregulated upon mitochondrial dys-
function and ER stress (Lu W et al., unpublished data).
This is consistent with emerging studies in muscle with
mitochondrial dysfunction and genetic disease indicating
a possibility that FGF21 could be induced in muscle
under metabolic and energy stress [34,36,37], which also
targets the adipose tissue. This further supports a gen-
eral role of FGF21 as a stress-responsive metabolic regu-
lator that modulates cellular energy homeostasis in
crisis. It would be interesting to know whether there is
coordination between the liver and muscle for inducing
FGF21 expression and contributing to serum FGF21
levels under stress. In respect to the hepatic biomarker
utility, it is therefore important to define a test condition
under which the muscle has a minimal or no input for
FGF21 expression. The importance of non-hepatic
FGF21 in muscle or other tissues under stress conditions
and its coordination among adipocytes, the primaryple types of stresses. Hepatic cellular and metabolic stresses imposed
FGF21 released from hepatocytes activates FGFR1-KLB complex in the
ction of abnormal metabolic parameters and metabolic insufficiency
back response, potential damages imparted by the stress to the liver
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http://www.biomedcentral.com/1471-230X/13/67target for FGF21, and liver should be an area of fruitful
future study.
Hepatic expression and blood levels of FGF21 under
normal fasting and feeding cycles or a 48 hr fasting are
low and vary widely among individuals in man. This char-
acteristic of human FGF21 differs from rodent FGF21 that
can be induced significantly by a 48 hr fasting or ketogenic
diet [50,63]. The inducible expression of FGF21 in muscle
under muscular stress in addition to the liver may also
contribute to the wide interindividual variation of fasting
levels of human serum FGF21. However, human serum
FGF21 can be consistently elevated during extreme fasting
(7 days) or starvation. Furthermore, both human and ro-
dent FGF21 appear to be inducible to a high and relatively
stable level under multiple stress conditions. All these
facts further highlight the role of FGF21 as a stress-
responsive factor.
Lastly, we show that both during transient regeneration
in response to injury and in hepatomas, the expression
pattern of the metabolic co-factor KLB is opposite to that
of FGF21 in liver. This opposite pattern of FGF21 and
KLB expression with no consistent change in FGFR4 may
indicate a cellular KLB-free state in the early regeneration
phase of the damaged liver, and is consistent with our
contention that in normal physiology the FGFR4-KLB
partnership is a negative regulator of hepatocyte prolifera-
tion as well as progression to hepatoma [41,44]. Depres-
sion of KLB may be essential to relieve the restriction on
hepatocyte expansion during normal response to injury
and restoration of normal liver physiology imposed by the
FGFR4-KLB partnership, of which the primary function is
to regulate bile acid synthesis.
Conclusion
Taken together, our data support the idea that FGF21 is a
stress-activated hepatokine and induced significantly in
the liver upon perturbation and disease development. This
stress-activated FGF21 expression may underlie the gener-
ally beneficial effects of FGF21 through alleviating liver
overload such as steatosis and counteracting potential
liver damage imposed by a variety of metabolic and cellu-
lar stresses [9,10] (Figure 8). Serum FGF21 levels likely re-
flects the original liver production source and is expected
to be a biomarker for functional status of the liver and
liver damage leading to hepatoma and disease of liver dys-
function. Liver biopsy has been the gold standard yet im-
perfect and invasive method with risks. There are also
serious limitations for the existing invasive biomarkers,
such as those used in FibroTest-ActiTest, AST/ALT and
AST/platelets ratio index (APRI). These limitations may
include poor sensitivity and specificity, indeterminate
ranges and poor predicative values [64]. New biomarkers
with better predictive values are needed. Future clinical
experiments are needed to directly compare the clinicalutility of serum FGF21 or combinatory utility of FGF21
with these existing biomarkers.
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